Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PYXS

Pyxis Oncology Inc

Last Close
Jul 26 • 04:00PM ET
3.88
Dollar change
+0.03
Percentage change
0.78 		%
Held by: IWM VTI VXF IWN VTWO IWC AVSC AVUV VTWV RSSL Scroll to Statements
IndexRUT P/E- EPS (ttm)-1.38 Insider Own19.65% Shs Outstand58.89M Perf Week11.49%
Market Cap228.49M Forward P/E- EPS next Y-1.31 Insider Trans0.00% Shs Float47.32M Perf Month20.87%
Income-57.80M PEG- EPS next Q-0.33 Inst Own45.48% Short Float7.43% Perf Quarter-9.77%
Sales16.15M P/S14.15 EPS this Y41.89% Inst Trans-1.79% Short Ratio5.99 Perf Half Y22.78%
Book/sh3.13 P/B1.24 EPS next Y-22.22% ROA-28.68% Short Interest3.52M Perf Year55.20%
Cash/sh2.69 P/C1.44 EPS next 5Y34.60% ROE-34.37% 52W Range1.35 - 6.85 Perf YTD115.56%
Dividend Est.- P/FCF- EPS past 5Y-118.72% ROI-28.35% 52W High-43.36% Beta1.25
Dividend TTM- Quick Ratio12.19 Sales past 5Y0.00% Gross Margin76.90% 52W Low187.41% ATR (14)0.27
Dividend Ex-Date- Current Ratio12.19 EPS Y/Y TTM56.95% Oper. Margin-414.02% RSI (14)61.65 Volatility8.82% 8.25%
Employees50 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin-358.00% Recom1.00 Target Price8.60
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q88.33% Payout- Rel Volume0.55 Prev Close3.85
Sales Surprise291.42% EPS Surprise74.85% Sales Q/Q- EarningsMay 14 BMO Avg Volume586.46K Price3.88
SMA2018.98% SMA509.10% SMA20014.45% Trades Volume319,923 Change0.78%
Date Action Analyst Rating Change Price Target Change
May-07-24Resumed Jefferies Buy $10
Feb-09-24Initiated BTIG Research Buy $8
Jan-23-24Initiated Leerink Partners Outperform $12
Sep-05-23Initiated RBC Capital Mkts Outperform $7
Nov-02-21Initiated Jefferies Buy $25
Nov-02-21Initiated Credit Suisse Outperform $19
Nov-02-21Initiated BofA Securities Neutral $16
Jun-28-24 04:30PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-10-24 07:30AM
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
(GlobeNewswire)
May-30-24 07:30AM
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-14-24 03:53PM
PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
08:40AM
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
(Zacks)
07:30AM Loading…
07:30AM
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
(GlobeNewswire)
May-09-24 07:30AM
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
(GlobeNewswire) +5.62%
Apr-12-24 09:55AM
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
(Zacks) -6.64%
Mar-28-24 04:30PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +12.44%
Mar-27-24 07:30AM
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
(GlobeNewswire) +9.66%
Mar-26-24 12:00PM
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
(Zacks)
Mar-21-24 01:53PM
PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023
(InvestorPlace) -8.66%
09:11AM
Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges
(GuruFocus.com)
07:30AM
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
(GlobeNewswire)
Mar-13-24 08:00AM
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
(GlobeNewswire) -6.14%
04:30PM Loading…
Mar-07-24 04:30PM
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
(GlobeNewswire) -9.63%
Mar-05-24 04:45PM
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
(GlobeNewswire)
Feb-27-24 08:00AM
Pyxis Oncology Announces $50 Million Private Placement
(GlobeNewswire) +33.26%
Dec-29-23 04:30PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +14.44%
Nov-28-23 07:00AM
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
(GlobeNewswire)
Nov-07-23 04:30PM
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
(GlobeNewswire)
Oct-23-23 11:27AM
Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop
(PR Newswire)
Oct-13-23 09:00AM
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
(PR Newswire)
Sep-27-23 09:18AM
Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
(GlobeNewswire)
Sep-14-23 05:03PM
Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc
(GuruFocus.com)
Aug-31-23 04:01PM
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
(GlobeNewswire) +6.42%
Aug-23-23 08:35AM
Pyxis Oncology Successfully Completes Acquisition of Apexigen
(GlobeNewswire)
Aug-11-23 07:00AM
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
(GlobeNewswire) +6.61%
Aug-01-23 04:01PM
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
(GlobeNewswire)
Jun-30-23 05:00PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
08:30AM Loading…
May-30-23 08:30AM
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
(GlobeNewswire)
May-24-23 06:45AM
Pyxis Oncology to Acquire Apexigen
(GlobeNewswire) -10.46%
May-11-23 07:00AM
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
(GlobeNewswire)
Mar-31-23 05:00PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -33.17%
Mar-30-23 02:16PM
Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go?
(TipRanks) +32.16%
Mar-22-23 06:45AM
Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update
(GlobeNewswire)
Mar-16-23 07:30AM
Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors
(GlobeNewswire) +7.46%
Feb-13-23 08:00AM
Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference
(GlobeNewswire)
Dec-23-22 04:45PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.79%
Dec-01-22 06:45AM
Pyxis Oncology Announces FDA Clearance of Two IND Applications
(GlobeNewswire)
Nov-01-22 06:30AM
Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update
(GlobeNewswire) -9.63%
Sep-30-22 05:00PM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Aug-15-22 07:00AM
Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update
(GlobeNewswire)
Jul-12-22 06:45AM
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-28-22 06:35AM
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference
(GlobeNewswire)
Jun-21-22 10:40AM
Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year
(Simply Wall St.)
May-19-22 06:35AM
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences
(GlobeNewswire)
May-13-22 08:03AM
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
(GlobeNewswire) -9.01%
May-07-22 10:34AM
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
(Simply Wall St.)
Apr-27-22 06:35AM
Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference
(GlobeNewswire)
Apr-13-22 06:35AM
Pyxis Oncology Announces Leadership Changes
(GlobeNewswire)
Apr-08-22 01:05PM
Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire)
Mar-29-22 11:00AM
Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology
(PR Newswire)
06:35AM
Pyxis Oncology Provides Corporate and Financial Update
(GlobeNewswire)
Mar-22-22 06:35AM
Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022
(GlobeNewswire) -8.04%
Jan-10-22 11:17AM
Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders
(Simply Wall St.)
Dec-15-21 08:00AM
Pyxis to be Added to Russell 2000® Index
(GlobeNewswire)
Dec-09-21 08:30AM
Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer
(GlobeNewswire)
Nov-15-21 07:15AM
Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
(GlobeNewswire)
Nov-10-21 08:00AM
Pyxis Oncology to Present at the Jefferies London Healthcare Conference
(GlobeNewswire)
Oct-08-21 03:31PM
Pyxis Oncology well positioned to advance its work against cancer amid public debut: CEO
(Yahoo Finance Video)
Oct-07-21 10:24PM
Pyxis Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connealy Pamela AnnCFO and COOSep 28 '23Buy1.878,00014,960818,532Sep 28 04:32 PM
Connealy Pamela AnnCFO and COOSep 27 '23Buy1.856,42611,868810,532Sep 27 06:36 PM
Wadhane JitendraChief Accounting OfficerSep 27 '23Buy1.872,5004,675226,937Sep 27 06:37 PM
Connealy Pamela AnnCFO and COOSep 25 '23Buy1.6712,00020,044804,106Sep 25 05:04 PM
Wadhane JitendraChief Accounting OfficerSep 25 '23Buy1.775,0008,850224,437Sep 25 05:05 PM
Connealy Pamela AnnCFO and COOSep 22 '23Buy1.745,0008,695792,106Sep 22 07:34 PM
Wadhane JitendraChief Accounting OfficerSep 22 '23Buy1.742,5004,349219,437Sep 22 07:35 PM
Sullivan LaraPresident and CEOSep 18 '23Sale2.108,54117,9362,403,882Sep 18 07:03 PM
Sullivan LaraPresident and CEOSep 14 '23Sale2.251002252,412,423Sep 18 07:03 PM
Sullivan LaraPresident and CEOSep 13 '23Sale2.273,0006,8162,597,265Sep 13 08:16 PM
Sullivan LaraPresident and CEOSep 12 '23Sale2.254,91711,0712,600,265Sep 13 08:16 PM
Sullivan LaraPresident and CEOSep 11 '23Sale2.2720,00045,4142,605,182Sep 13 08:16 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.